PhysIOL Acquires a Majority Stake in Optikon
PhysIOL announced that it has entered into a definitive agreement under which PhysIOL will acquire a majority stake in opthalmic device manufacturer Optikon. Terms of the deal were not disclosed.
Italy-based Optikon develops and markets ophthalmic devices, including phaco, vitrectomy, and diagnostic equipment. Optikon's product portfolio includes the R-Evolution and Pulsar machines.
"Optikon's range of products in anterior and posterior segments fits perfectly with PhysIOL's innovative IOL portfolio, and entering into this partnership will allow PhysIOL to establish itself as a global platform for cataract and refractive surgery" Marc Nolet, Chief Executive Officer of PhysIOL, said in a company news release. "We believe this acquisition will strengthen the group's product portfolio and support our position as a major player in ophthalmology. Optikon's premium products and solutions form an essential part of the group’s growth strategy going forward."
"We are very enthusiastic about the opportunity to be part of the PhysIOL organization. The combined resources of both companies will create a new leading company in the ophthalmology market and a viable alternative to the global players in place," said Enrico Orefice, Chief Executive Officer of Optikon.
You must be logged in to leave a comment.